Impact of Prophylactic Ranibizumab to Prevent Neovascular Age-Related Macular Degeneration On Eyes With Intermediate Age-Related Macular Degeneration

Overview

Journal Transl Vis Sci Technol

Specialties Biomedical Engineering
Ophthalmology

Date 2023 Sep 1

PMID 37656449

Authors

Clement K Chan

Wesley T Beaulieu

Brandon J Lujan

Maziar Lalezary

Daniella Lent-Schochet

Therlinder Lo

Glenn Yiu

Affiliations

Soon will be listed here.

Abstract

Purpose: The purpose of this study was to determine the impact of prophylactic ranibizumab (PR) injections given every 3 months in eyes with intermediate nonexudative age-related macular degeneration (AMD) on drusen volume, macular layer thicknesses, and progression of geographic atrophy (GA) area over 24 months in the PREVENT trial.

Methods: This post hoc analysis of the prospective PREVENT trial compared eyes with intermediate AMD randomized to PR versus sham injections to determine rates of conversion to neovascular AMD over 24 months. Drusen area and volume, macular thickness and volume, and retinal layer thicknesses were measured on spectral-domain optical coherence tomography images and analyzed. Masked grading of GA area and subretinal drusenoid deposits (SDDs) using fundus autofluorescence images was performed.

Results: There were no statistical differences in drusen area and volumes between groups, and similar reductions in central subfield thickness, mean cube thickness, cube volume, and retinal sublayer thickness from baseline to 24 months (P = 0.018 to < 0.001), with no statistical differences between groups in any of these anatomic parameters. These findings were not impacted by the presence or absence of SDD. Among the 9 eyes with GA in this study, mean GA growth rate from baseline to 24 months was 1.34 +/- 0.79 mm2/year after PR and 1.95 +/- 1.73 mm2/year in sham-treated eyes (P = 0.49), and similarly showed no statistical difference with square root transformation (P = 0.61).

Conclusions: Prophylactic ranibizumab given every 3 months did not appear to affect drusen volume, macular thinning, or GA progression in eyes with intermediate AMD.

Translational Relevance: This work investigates the impact of PR on progressive retinal degeneration in a clinical trial.

Citing Articles

Longer recreational screen time contributes to the risk of age-related macular degeneration: a UK Biobank cohort study and two-sample Mendelian randomisation.

Huang Y, Zhang X, Liang L, Jiang Y, Li B, Zhu X J Glob Health. 2025; 15:04029.

PMID: 39883882 PMC: 11781809. DOI: 10.7189/jogh.15.04029.

References

Danis R, Domalpally A, Chew E, Clemons T, Armstrong J, SanGiovanni J . Methods and reproducibility of grading optimized digital color fundus photographs in the Age-Related Eye Disease Study 2 (AREDS2 Report Number 2). Invest Ophthalmol Vis Sci. 2013; 54(7):4548-54. PMC: 3706107. DOI: 10.1167/iovs.13-11804. View

Kitchen C . Nonparametric vs parametric tests of location in biomedical research. Am J Ophthalmol. 2009; 147(4):571-2. PMC: 2743502. DOI: 10.1016/j.ajo.2008.06.031. View

Sadda S, Chakravarthy U, Birch D, Staurenghi G, Henry E, Brittain C . CLINICAL ENDPOINTS FOR THE STUDY OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION. Retina. 2016; 36(10):1806-22. PMC: 5384792. DOI: 10.1097/IAE.0000000000001283. View

Vitale S, Clemons T, Agron E, Ferris 3rd F, Domalpally A, Danis R . Evaluating the Validity of the Age-Related Eye Disease Study Grading Scale for Age-Related Macular Degeneration: AREDS2 Report 10. JAMA Ophthalmol. 2016; 134(9):1041-7. PMC: 8371745. DOI: 10.1001/jamaophthalmol.2016.2383. View

Behbehani R, Abu Al-Hassan A, Al-Salahat A, Sriraman D, Oakley J, Alroughani R . Optical coherence tomography segmentation analysis in relapsing remitting versus progressive multiple sclerosis. PLoS One. 2017; 12(2):e0172120. PMC: 5305239. DOI: 10.1371/journal.pone.0172120. View

Chiang T, Keenan T, Agron E, Liao J, Klein B, Chew E . Macular Thickness in Intermediate Age-Related Macular Degeneration Is Influenced by Disease Severity and Subretinal Drusenoid Deposit Presence. Invest Ophthalmol Vis Sci. 2020; 61(6):59. PMC: 7415904. DOI: 10.1167/iovs.61.6.59. View

van Leeuwen R, Klaver C, Vingerling J, Hofman A, de Jong P . Epidemiology of age-related maculopathy: a review. Eur J Epidemiol. 2003; 18(9):845-54. DOI: 10.1023/a:1025643303914. View

Ferris 3rd F, Wilkinson C, Bird A, Chakravarthy U, Chew E, Csaky K . Clinical classification of age-related macular degeneration. Ophthalmology. 2013; 120(4):844-51. PMC: 11551519. DOI: 10.1016/j.ophtha.2012.10.036. View

Schuman S, Koreishi A, Farsiu S, Jung S, Izatt J, Toth C . Photoreceptor layer thinning over drusen in eyes with age-related macular degeneration imaged in vivo with spectral-domain optical coherence tomography. Ophthalmology. 2009; 116(3):488-496.e2. PMC: 2695995. DOI: 10.1016/j.ophtha.2008.10.006. View

10.

Keenan T, Agron E, Domalpally A, Clemons T, van Asten F, Wong W . Progression of Geographic Atrophy in Age-related Macular Degeneration: AREDS2 Report Number 16. Ophthalmology. 2018; 125(12):1913-1928. PMC: 6246813. DOI: 10.1016/j.ophtha.2018.05.028. View

11.

Bindewald A, Schmitz-Valckenberg S, Jorzik J, Dolar-Szczasny J, Sieber H, Keilhauer C . Classification of abnormal fundus autofluorescence patterns in the junctional zone of geographic atrophy in patients with age related macular degeneration. Br J Ophthalmol. 2005; 89(7):874-8. PMC: 1772741. DOI: 10.1136/bjo.2004.057794. View

12.

Lamin A, Oakley J, Dubis A, Russakoff D, Sivaprasad S . Changes in volume of various retinal layers over time in early and intermediate age-related macular degeneration. Eye (Lond). 2018; 33(3):428-434. PMC: 6460706. DOI: 10.1038/s41433-018-0234-9. View

13.

Grunwald J, Pistilli M, Daniel E, Ying G, Pan W, Jaffe G . Incidence and Growth of Geographic Atrophy during 5 Years of Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology. 2017; 124(1):97-104. PMC: 5234734. DOI: 10.1016/j.ophtha.2016.09.012. View

14.

Maguire M, Martin D, Ying G, Jaffe G, Daniel E, Grunwald J . Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology. 2016; 123(8):1751-1761. PMC: 4958614. DOI: 10.1016/j.ophtha.2016.03.045. View

15.

Wang J, Foran S, Smith W, Mitchell P . Risk of age-related macular degeneration in eyes with macular drusen or hyperpigmentation: the Blue Mountains Eye Study cohort. Arch Ophthalmol. 2003; 121(5):658-63. DOI: 10.1001/archopht.121.5.658. View

16.

Daniel E, Maguire M, Grunwald J, Toth C, Jaffe G, Martin D . Incidence and Progression of Nongeographic Atrophy in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Clinical Trial. JAMA Ophthalmol. 2020; 138(5):510-518. PMC: 7082767. DOI: 10.1001/jamaophthalmol.2020.0437. View

17.

Chan C, Lalezary M, Abraham P, Elman M, Beaulieu W, Lin S . Prophylactic Ranibizumab to Prevent Neovascular Age-Related Macular Degeneration in Vulnerable Fellow Eyes: A Randomized Clinical Trial. Ophthalmol Retina. 2022; 6(6):484-494. DOI: 10.1016/j.oret.2022.01.019. View

18.

Friedman D, OColmain B, Munoz B, Tomany S, McCarty C, de Jong P . Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004; 122(4):564-72. DOI: 10.1001/archopht.122.4.564. View

19.

Rogala J, Zangerl B, Assaad N, Fletcher E, Kalloniatis M, Nivison-Smith L . In vivo quantification of retinal changes associated with drusen in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2015; 56(3):1689-700. DOI: 10.1167/iovs.14-16221. View

20.

Tan J, Yang Y, Jiang H, Liu C, Deng Z, Lam B . The measurement repeatability using different partition methods of intraretinal tomographic thickness maps in healthy human subjects. Clin Ophthalmol. 2016; 10:2403-2415. PMC: 5136365. DOI: 10.2147/OPTH.S117494. View